As such, CD22 or tandem CD19 and CD22 targeting CAR-T cells are being pursued in treating B cell malignancies such as non-Hodgkin lymphomas and acute lymphoblastic leukemia [43,44,45]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.